• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Mast Therapeutics initiates Phase 2 study of AIR001

According to Mast Therapeutics the first patient has been enrolled in a Phase 2 study of its AIR001 sodium nitrite inhalation solution in patients with heart failure with preserved ejection fraction (HFpEF). The multicenter, randomized, double-blind, placebo-controlled is expected to enroll 100 patients.

The company announced earlier this year that the INDIE-HFpEF study would be sponsored by Duke Clinical Research Institute (DCRI) and conducted at centers associated with the Heart Failure Clinical Research Network (HFN). In February 2016, Mast reported positive results from a Phase 2a clinical study of AIR001 in HFpEF patients conducted at the Mayo Clinic.

Mast Therapeutics CEO Brian M. Culley said, “AIR001, a sodium nitrite solution administered via inhalation, has potential as an effective treatment for heart failure, and we are pleased that patient enrollment is underway. This study will advance our efforts to characterize the efficacy of AIR001 for patients who have heart failure with preserved ejection fraction. There are more than 1 million heart failure hospitalizations each year in the US, about half of which involve patients with HFpEF. Currently, no proven effective therapeutic agents are available for this large patient population. We look forward to continuing to support DCRI and the HFN on this study.”

AIR001 is also in Phase 2 development for the treatment of pulmonary arterial hypertension.

Read the Mast Therapeutics press release.

Share

published on August 1, 2016

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews